Treatment Recommendation for Toxoplasma Chorioretinitis with Co-trimoxazole Allergy
Use pyrimethamine plus sulfadiazine plus folinic acid (leucovorin) for 4-6 weeks, continuing for at least 1-2 weeks after clinical resolution of the active chorioretinitis. This is the standard alternative regimen when co-trimoxazole cannot be used 1.
Specific Dosing Regimen
For Adults and Older Children:
Pyrimethamine:
- Loading dose: 2 mg/kg/day orally divided twice daily for the first 2 days (maximum 50 mg/day)
- Maintenance: 1 mg/kg/day orally once daily thereafter (maximum 25 mg/day) 1
Sulfadiazine:
- Loading dose: 75 mg/kg orally once
- Maintenance: 100 mg/kg/day orally divided twice daily 1
Folinic acid (leucovorin) - CRITICAL:
- 10-20 mg orally three times per week 1
- Never substitute folic acid for folinic acid - this is a critical error that can lead to treatment failure 1
Corticosteroids (if indicated):
Add prednisone 1 mg/kg/day divided twice daily if:
- Severe chorioretinitis in vision-threatening macular area
- Start corticosteroids only after 72 hours of anti-Toxoplasma therapy 1
Duration of Treatment
Continue treatment for at least 1-2 weeks after resolution of clinical signs (sharpening of lesion borders and/or scarring), with a total duration of 4-6 weeks 1. Some experts recommend longer courses (up to 3 months in children based on French experience, up to 4 months in adults) 1.
Ophthalmologic follow-up every 2-3 weeks is mandatory to determine optimal treatment duration 1.
Alternative Regimens (If Sulfadiazine Also Cannot Be Used)
The guidelines acknowledge that pyrimethamine plus clindamycin or azithromycin have been tried by some U.S. experts, though there is no systematic published experience with these alternatives 1. Given the lack of high-quality evidence for alternatives and your specific constraint (no atovaquone available), the pyrimethamine-sulfadiazine combination remains your best option.
If Sulfadiazine is Also Contraindicated:
Consider pyrimethamine plus clindamycin (though evidence is limited):
- Pyrimethamine: dosed as above
- Clindamycin: 600 mg orally four times daily (adult dosing)
- Folinic acid: as above 1
Critical Monitoring Requirements
Weekly monitoring during treatment:
- Complete blood count (CBC) - pyrimethamine can cause bone marrow suppression
- Watch for thrombocytopenia, leukopenia, megaloblastic anemia
- If bone marrow depression occurs, increase leucovorin to 5-15 mg daily until hematopoiesis normalizes 2
Sulfadiazine-specific monitoring:
- Ensure adequate hydration to prevent crystalluria
- Monitor renal function
- Watch for hypersensitivity reactions (rash, fever)
Important Caveats
Evidence Quality Considerations:
The 2017 Pediatrics guidelines 1 explicitly state there are no comparative pediatric trials on relative efficacy of different treatment regimens for acute toxoplasmic chorioretinitis. In adults, there are only a few comparative trials, and there is lack of high-quality evidence to determine the best treatment option 1.
However, the pyrimethamine-sulfadiazine combination is the most established alternative to co-trimoxazole based on decades of clinical experience. Research evidence shows comparable efficacy between co-trimoxazole and pyrimethamine-sulfadiazine regimens 3, 4.
Common Pitfalls to Avoid:
Using folic acid instead of folinic acid - this is explicitly contraindicated and can lead to treatment failure 1
Starting corticosteroids too early - wait 72 hours after initiating anti-Toxoplasma therapy to avoid worsening infection 1
Stopping treatment too early - continue for at least 1-2 weeks after clinical resolution, not just when symptoms improve 1
Inadequate monitoring - pyrimethamine can cause significant bone marrow suppression requiring weekly CBC monitoring
Poor hydration with sulfadiazine - can lead to crystalluria and renal complications
Pyrimethamine Access:
If obtaining pyrimethamine is difficult, the guidelines provide specific instructions: contact Walgreens Specialty Pharmacy at 1-800-222-4991, mark as "STAT/URGENT" for same-day delivery, and request no delay for insurance clearance. For uninsured patients, medication is available without charge 1.
This regimen prioritizes visual outcomes and prevention of permanent vision loss, which directly impacts quality of life - the primary outcome that matters most in toxoplasmic chorioretinitis.